Number of suitable individuals: CDEC mentioned the uncertainty in the amount of individuals with moderately intense to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people that are categorized as getting mild or average ailment could have a serious bleeding phenotype, https://nicholasi134mno8.blgwiki.com/user